Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF.
Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF.
复制标题
使用 CD80 修饰的乳腺癌细胞和 GM-CSF 对转移性乳腺癌患者进行免疫。
DOI：
10.1007/978-1-4615-5357-1_79
复制
发表时间：
1998
影响因子：
--
通讯作者：
W. Urba
中科院分区：
文献类型：
--
作者：
D. Schoof;J. Smith;M. L. Disis;P. Brant;W. Wood;T. Doran;E. Johnson;W. Urba
已经在多种人类肿瘤上鉴定出肿瘤相关抗原。这些抗原中的每一种都可以作为免疫应答的靶标，其结果将是消除肿瘤细胞。这种免疫应答的一个重要组成部分是将抗原呈递给潜在的效应细胞。这可以通过宿主专职抗原呈递细胞（APC）（如树突状细胞）或肿瘤本身来实现。缺乏关于肿瘤相关抗原的信息以及它们在体内明显缺乏免疫原性使针对乳腺癌的免疫应答的诱导复杂化。我们已经开始努力增加表达至少一种肿瘤相关抗原Her 2/neu的乳腺癌细胞系的抗原递呈细胞（APC）功能。her 2/neu基因编码与表皮生长因子受体同源的185 kd跨膜酪氨酸激酶受体。以往的研究表明，Her 2/neu在20-30%的乳腺和卵巢肿瘤中过表达，并且其过表达与不良预后相关[1，2]，研究还表明Her 2/neu也可以作为肿瘤相关抗原发挥作用。从卵巢肿瘤中分离的细胞毒性T淋巴细胞（CTL）特异性识别Her 2/neu衍生肽，可以杀死Her 2/neu+肿瘤，但不能杀死Her 2/neu-肿瘤[3，4]。在转移性乳腺癌患者的血清中可发现Her 2/neu抗体，但在对照受试者中未发现[5，6]。此外，用Her 2/neu肽免疫的大鼠产生了CD 4 + T细胞免疫应答以及抗体应答[7]，用Her 2/neu肽免疫的小鼠产生了Her 2/neu特异性肿瘤免疫[8]。
Tumor-associated antigens have been identified on a variety of human neoplasms. Each of these antigens may be able to serve as a target for an immune response, the result of which would be elimination of the tumor cell. An essential component of this immune response is the presentation of antigen to potential effector cells. This can be accomplished via host professional antigen-presenting cells (APC), such as dendritic cells, or via the tumor itself. The lack of information about tumor-associated antigens and their apparent lack of immunogenicity in vivo complicate the induction of immune responses against breast cancers. We have undertaken the effort to increase the antigen-presenting cell (APC) function of a breast cancer line that expresses at least one tumor-associated antigen, Her2/neu. The her2/neu gene encodes a 185-kd transmembrane tyrosine kinase receptor that shares homology with the epidermal growth factor receptor. Previous studies indicated that Her2/neu was overexpressed by 20–30% of breast and ovarian tumors and its overexpression has been associated with a poor prognosis [1, 2], Studies have also suggested that Her2/neu can also function as a tumor-associated antigen. Cytotoxic T lymphocytes (CTL) isolated from ovarian tumors specifically recognizes Her2/neu-derived peptides and can kill Her2/neu+ tumors but not Her2/neu- tumors [3, 4]. Antibodies to Her2/neu can be found in the sera of patients with metastatic breast cancer but not in control subjects [5,6]. In addition, rats immunized with Her2/neu peptides developed CD4+ T cell immune responses as well as antibody responses [7] and mice immunized with Her2/neu peptides developed Her2/neu-specific tumor immunity [8].
登录
查看更多内容
影响因子：
4.4
作者：
M. Jenkins;P. Taylor;S. Norton;K. Urdahl
通讯作者：
M. Jenkins;P. Taylor;S. Norton;K. Urdahl
影响因子：
4.4
作者：
M. Disis;J. Gralow;H. Bernhard;S. Hand;W. D. Rubin;M. Cheever
通讯作者：
M. Disis;J. Gralow;H. Bernhard;S. Hand;W. D. Rubin;M. Cheever
影响因子：
56.9
作者：
TOWNSEND, SE;ALLISON, JP
通讯作者：
ALLISON, JP
影响因子：
45.3
作者：
Disis, ML;Pupa, SM;Cheever, MA
通讯作者：
Cheever, MA
影响因子：
56.9
作者：
SLAMON, DJ;GODOLPHIN, W;PRESS, MF
通讯作者：
PRESS, MF